Aratana Therapeutics, Inc.
PETX
PETX was delisted on the 17th of July, 2019.
105 hedge funds and large institutions have $227M invested in Aratana Therapeutics, Inc. in 2017 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 48 increasing their positions, 15 reducing their positions, and 11 closing their positions.
220% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 15
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
82% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 11
55% more capital invested
Capital invested by funds: $146M → $227M (+$80.6M)
40% more call options, than puts
Call options by funds: $708K | Put options by funds: $505K
7% more funds holding
Funds holding: 98 → 105 (+7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$11M |
| 2 |
BC
Broadfin Capital
New York
|
+$9.16M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$4.44M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$3.72M |
| 5 |
AIC
AWM Investment Company
New York
|
+$3.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$5.17M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.84M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
-$1.39M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.37M |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$346K |
PETX Hedge Fund Activity: Q2 2017 in Review
105 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Aratana Therapeutics, Inc. (PETX) for Q2 2017, worth a combined $227M — up 55% from $146M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new PETX positions and 11 closed out — a net gain of 9 holders — while 48 added to existing stakes and 15 trimmed.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $11M. The largest seller was Jennison Associates, exiting entirely with an estimated $5.17M sold.
- 105 institutional investors held Aratana Therapeutics, Inc. (PETX) as of Q2 2017, up from 98 in Q1 2017.
- Funds reported $227M of Aratana Therapeutics, Inc. stock for Q2 2017, up 55% quarter-over-quarter.
- 20 funds opened new Aratana Therapeutics, Inc. positions in Q2 2017 and 11 closed out, a net change of +9 holders.
- The largest Aratana Therapeutics, Inc. buyer in Q2 2017 was Janus Henderson Group, an estimated $11M added.
- The largest Aratana Therapeutics, Inc. seller in Q2 2017 was Jennison Associates, an estimated $5.17M sold.
Based on aggregated 13F filings for Q2 2017.